gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

Article

Send article

Non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases using MRI radiomics

MRT Radiomics zur nicht-invasiven Vorhersage des BRAF-Mutationsstatus in Patienten mit zerebralen Melanommetastasen

Meeting Abstract

Search Medline for

  • presenting/speaker Anna-Katharina Meißner - University Hospital Cologne, University of Cologne, Department of General Neurosurgery, Köln, Deutschland; University Hospital Cologne, University of Cologne, Department of Stereotactic and Functional Neurosurgery, Köln, Deutschland
  • Robin Gutsche - Research Centre Jülich, Institute of Neuroscience and Medicine, Jülich, Deutschland
  • Norbert Galldiks - Research Centre Jülich, Institute of Neuroscience and Medicine, Jülich, Deutschland; University Hospital Cologne, University of Cologne, Department of Neurology, Köln, Deutschland; Universities of Aachen, Bonn, Cologne and Düsseldorf, Center for Integrated Oncology (CIO), Köln, Deutschland
  • Martin Kocher - University Hospital Cologne, University of Cologne, Department of Stereotactic and Functional Neurosurgery, Köln, Deutschland; Research Centre Jülich, Institute of Neuroscience and Medicine, Jülich, Deutschland
  • Maximilian I. Ruge - University Hospital Cologne, University of Cologne, Department of Stereotactic and Functional Neurosurgery, Köln, Deutschland; Universities of Aachen, Bonn, Cologne and Düsseldorf, Center for Integrated Oncology (CIO), Köln, Deutschland
  • Stephanie Theresa Jünger - University Hospital Cologne, University of Cologne, Department of General Neurosurgery, Köln, Deutschland
  • Cornelia Mauch - University Hospital Cologne, University of Cologne, Department of Dermatology, Köln, Deutschland
  • Stefan Grau - University Hospital Cologne, University of Cologne, Department of General Neurosurgery, Köln, Deutschland; Universities of Aachen, Bonn, Cologne and Düsseldorf, Center for Integrated Oncology (CIO), Köln, Deutschland
  • Philipp Lohmann - University Hospital Cologne, University of Cologne, Department of Stereotactic and Functional Neurosurgery, Köln, Deutschland; Research Centre Jülich, Institute of Neuroscience and Medicine, Jülich, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP082

doi: 10.3205/21dgnc370, urn:nbn:de:0183-21dgnc3705

Published: June 4, 2021

© 2021 Meißner et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: Malignant melanomas frequently develop brain metastases. Targeted therapies such as BRAF inhibitors have shown relevant intracranial response rates in initial trials. The most frequent BRAF V600E mutation occurs in up to 60% of melanomas. However, recent studies reported a significant discrepancy with respect to the mutational status of the extracranial melanoma and melanoma brain metastases. We evaluated the potential of MR-radiomics for the non-invasive diagnosis of BRAF status in brain metastases.

Methods: Forty-four patients with 48 brain metastases secondary to malignant melanoma underwent brain tumor surgery with subsequent molecular tissue analysis of the BRAF mutational status. All patients received a preoperative MRI including contrast-enhanced (CE) T1- and T2-weighted sequences. Brain metastases were manually segmented based on CE T1-weigthed MRI. After image preprocessing 2632 radiomics features were extracted using pyradiomics. Patients were randomly assigned to a training and a test dataset in a ratio of 50/50. To test predictive performance multiple algorithms were trained based on 5-fold cross validation. Finally, the best performing model was applied to the test dataset to evaluate model generalizability.

Results: Twenty-one patients (48%) showed a BRAF V600E mutation. In the test dataset, the radiomics model using a support vector machine classifier yielded an area under the receiver operating characteristic curve (AUC) of 0.8 (accuracy, 77%; sensitivity, 70%; specificity, 83%) for prediction of the BRAF mutation status.

Conclusion: MRI radiomics allows a non-invasive prediction of the BRAF V600E mutation status in patients with melanoma brain metastases. Further evaluation of the developed model is ongoing.

Figure 1 [Fig. 1], Figure 2 [Fig. 2]